Grant: Doctoral Research Award: Canada Graduate Scholarships
Unity Health Toronto
$120,000.00
Mainstreaming Genetics: Evaluation of a digital application to scale and spread oncologist-initiated genetic testing.
EF 2024-25
Résumé
Genetic testing can change how we care for cancer patients. It is often the first test for many patients with a new cancer diagnosis. Some cancer centers are "mainstreaming genetic testing", which means oncologists - instead of genetics experts - will order a genetic test without traditional genetic counselling before testing. They may use paper-based patient pamphlets or checklists instead. This method can lead to negative feelings and bad experiences for patients and their families. Genetic counselling can help patients deal with the impacts of a life-changing genetic test result. Digital tools for oncologist-initiated tests can help with these challenges by making genetic counselling more accessible. Yet, no such tool exists for cancer genetic services.
To solve this problem, we created and want to test a new digital tool called the Mainstream Adviser to provide virtual genetic counselling and education to patients. We hope this tool will supplement standard care and improve the genetic testing process for cancer patients, their families and doctors. We co-developed the Mainstream Adviser with the help of patients, doctors and fellow researchers. We now want to conduct a randomized controlled trial with approximately 160 patients, where 80 will be assigned to receive the Mainstream Adviser and 80 will receive standard care. This study method will measure the amount of distress and several other outcomes that patients experience using the Mainstream Adviser compared to the current standard model of care. We will compare the experiences of patients who used the Mainstream Adviser to patients who received mainstream care.
This research study will create a new digital tool that puts the patient at the center of the genetic testing process. In addition to reducing wait times, we hope this tool will assist with decision-making, educating patients and improving communication between patients and their doctors while reducing the overall burden on healthcare providers.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
518150
Name
Assamad Daniel
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Doctoral Research Awards - B
Projecttitle
Mainstreaming Genetics: Evaluation of a digital application to scale and spread oncologist-initiated genetic testing.
Programtype2
Studentship Programs
Orgnameinp2
Unity Health Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cancer Genetic Testing; Digital Health Tools; Genetic Counselling; Genetics; Genetics Service Delivery; Health Services Research; Health Technology Assessment; Mainstreaming; Patient-Centred Care; Randomized Controlled Trial
Abstract
Genetic testing can change how we care for cancer patients. It is often the first test for many patients with a new cancer diagnosis. Some cancer centers are "mainstreaming genetic testing", which means oncologists - instead of genetics experts - will order a genetic test without traditional genetic counselling before testing. They may use paper-based patient pamphlets or checklists instead. This method can lead to negative feelings and bad experiences for patients and their families. Genetic counselling can help patients deal with the impacts of a life-changing genetic test result. Digital tools for oncologist-initiated tests can help with these challenges by making genetic counselling more accessible. Yet, no such tool exists for cancer genetic services.
To solve this problem, we created and want to test a new digital tool called the Mainstream Adviser to provide virtual genetic counselling and education to patients. We hope this tool will supplement standard care and improve the genetic testing process for cancer patients, their families and doctors. We co-developed the Mainstream Adviser with the help of patients, doctors and fellow researchers. We now want to conduct a randomized controlled trial with approximately 160 patients, where 80 will be assigned to receive the Mainstream Adviser and 80 will receive standard care. This study method will measure the amount of distress and several other outcomes that patients experience using the Mainstream Adviser compared to the current standard model of care. We will compare the experiences of patients who used the Mainstream Adviser to patients who received mainstream care.
This research study will create a new digital tool that puts the patient at the center of the genetic testing process. In addition to reducing wait times, we hope this tool will assist with decision-making, educating patients and improving communication between patients and their doctors while reducing the overall burden on healthcare providers.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Assamad, Daniel
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~